ADME Toxicology Testing Market Report 2019-2029 By Technology (Cell Culture, OMICS Tech), by Application (Systemic Toxicity, Renal Toxicity), by Method, by Region and Segment Forecasts
Product Code: RP-ID-10166335 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10166335
Market Overview:
ADME Toxicology Testing Market Report 2019-2029 By Technology (Cell Culture, OMICS Tech), by Application (Systemic Toxicity, Renal Toxicity), by Method, by Region and Segment Forecasts
Toxicological tests of absorption, distribution, metabolism and excretion (ADME) are used to test toxic reactions caused by molecules in clinical studies on systemic factors and reactions such as chemistry, pharmaceuticals and genetics. These toxicological test procedures help in the effective development of drugs, which limits or prevents toxic reactions to the body when administered. Toxicity levels are decided on the results of a series of tests conducted under almost natural conditions, which represent almost real-time reactions between the drug and the host.
Market Overview and Trends
The market is driven by the increase in the relationship between late-stage drug failures, resulting in lost valuable time and investments in drug development. The growth and increasing adoption of OMICS technology should also foster revenue generation in the coming years. North America is the largest market for ADME toxicological tests due to the presence of a large number of pharmaceutical companies competing for the commercial launch of new molecules. The developing regions of Asia Pacific and Latin America are destined to grow considerably as many multinational and local players work to enter the market. They are also trying to improve their grip on markets that present opportunities for innovation and growth
Factors Influencing the Market Growth:
• Newer technologies for toxicity testing as most of the upcoming molecules fail regulatory approval in their last stages
• Expanding number of medication improvements which require continuous drug testing
Factors Restraining the Market Growth:
• Skilled expertise and software that can handle and store multiple sets of data at a rapid pace
• Regulatory changes from governing bodies such as U.S. FDA
Market Segmentation 2019-2029:
The ADME Toxicology Testing market is segmented by Technology (Cell Culture, OMICS Tech), By Application (Systemic Toxicity, Renal Toxicity), By Method, By Region, And Segment Forecasts
Market Segmentation Covered:
• Global ADME Toxicology Testing Technologies Market 2019-2029
– Global Cell Culture Market 2019-2029
– Global High Throughput Market 2019-2029
– Global Molecular Imaging Market 2019-2029
– Global OMICS Technology Market 2019-2029
• Global ADME Toxicology Testing Applications Market 2019-2029
– Global Systemic Toxicity Market 2019-2029
– Global Renal Toxicity Market 2019-2029
– Global Hepatotoxicity Market 2019-2029
– Global Neurotoxicity Market 2019-2029
– Global Other Toxicities Market 2019-2029
• Global ADME Toxicology Testing Method Market 2019-2029
– Global Cellular Assay Market 2019-2029
– Global Biochemical Assay Market 2019-2029
– Global In-Silica Market 2019-2029
– Global Ex-vivo Market 2019-2029
Geographic Breakdown
Focused regional forecasts and analysis explore the future opportunities:
• North America Market, 2019-2029
• Europe Market, 2019-2029
• Asia-Pacific Market, 2019-2029
• LAMEA Market, 2019-2029
Competitive Analysis:
• Research and development is the primary strategy adopted by the key players in the ADME Toxicology Testing market.
• These companies have developed various strategies and developments such as product launch, partnerships, mergers & acquisitions, joint venture, and collaborations.
Major Market Players:
Accelrys Inc.; Agilent Technologies, Inc.; Albany Molecular Research Inc.; Beckman Coulter Inc.; Catalent Inc.; Charles River Laboratories International Inc.; AbbVie; Actelion Pharmaceuticals; Amgen; Biocon; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Cipla; and CymaBay Therapeutics.
Key questions answered by this report:
• What is the current size of the total global ADME Toxicology Testing market?
• How much will this market be worth from 2018 to 2029?
• How is the ADME Toxicology Testing market evolving?
• What is driving and restraining the ADME Toxicology Testing market?
• What are the market shares of each segment of the overall ADME Toxicology Testing market currently and how will these change to 2029?
• What are the main submarkets and how much revenue will each ADME Toxicology Testing market submarket account for over the next 10 years to 2029 and why?
• How will the market shares for each ADME Toxicology Testing market submarket develop from 2018 to 2029?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve to 2029?
• What are the largest national markets for ADME Toxicology Testing market? What is the current status and how will it develop over the next ten years? What are their forecasts for 2019-2029?
• Who are the most prominent companies, and what are their activities and outlooks?
• What are the main trends that will affect the ADME Toxicology Testing market between 2018 and 2029?
Kenneth Research’s study is intended for anyone requiring commercial analyses for the ADME Toxicology Testing market. You find data, trends and predictions.
Buy our report today ADME Toxicology Testing Market 2019-2029: By Technology (Cell Culture, OMICS Tech), By Application (Systemic Toxicity, Renal Toxicity), By Method, By Region, And Segment Forecasts
Kenneth Research is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sales@kennethresearch.com
Agilent Technologies, Inc.
Albany Molecular Research Inc.
Beckman Coulter Inc.
Catalent Inc.
Charles River Laboratories International Inc.
AbbVie
Actelion Pharmaceuticals
Amgen
Biocon
BioMarin
Boehringer Ingelheim
Bristol-Myers Squibb
Cipla
CymaBay Therapeutics.
Related Reports
Study Period : 2023-2035
Report Format : PDF,PPT
Delivery Timeline : 48-72 Business Hours
Proof of Quality & Reliability
